New Lab Provides for Early Stage Testing

Lyon-based Novasep has announced plans to build a new synthesis laboratory and a kilo lab for its US facility. This extension will allow the French company to produce the initial kilogram scale batches of synthetic molecules that are needed for biological testing and pre-clinical trials.

Novasep’s investment is a direct response to an increasing demand from US customers for its services that accelerate early stage development and ease of production scale-up. The new laboratory will be located at Novasep’s facility in Boothwyn (PA).

“This US undertaking is part of our ‘Back to Basics’ strategy we have been implementing for more than two years now,” said Thierry Van Nieuwenhove, president of the Synthesis BU. “Novasep is adapting its CMO services to the US market where flexibility and proximity to our customers is required.”

Novasep will equip the US facility with reactors up to 50L in size. The new laboratory will feature cryogenic capacities as well as standard chemistry. Last year, the company made a significant €10M ($11M) investment in a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France, thereby expanding its bioconjugation services. The company continues to strengthen its proven track record in process development and technology transfer. All of Novasep’s commercial scale facilities have successfully passed FDA inspection.